Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock
NEW YORK, Jan. 15, 2019 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, […]